Quan Fei

Dr. Quan Fei

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2024 in Cancer Research
Verified
Journal Article
Closed access
JNJianhua Nie
Jianhua Nie
SZShuyuan Zhang
Shuyuan Zhang
YGYing Guo
Ying Guo
CLCaiqi Liu
Caiqi Liu
JSJiaqi Shi
Jiaqi Shi
TZTongsen Zheng
Tongsen Zheng
Biliary tract cancer (BTC), encompassing diseases such as intrahepatic (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer, is not only increasing but also poses a significant and urgent health threat due to its high malignancy. Genomic differences point to the possibility that these subtypes represent distinct diseases. Elucidation of the specific distribution of T-cell subsets, critical to cancer immunity, across these diseases could provide better insights into the unique biology of BTC subtypes and help identify potential precision medicine strategies. To address this, we conducted single-cell RNA sequencing and T-cell receptor sequencing on CD3+ T cells from 36 samples from 16 patients with BTC across all subtypes and analyzed 355 pathologic slides to examine the spatial distribution of T cells and tertiary lymphoid structures. Compared with ICC and gallbladder cancer, ECC possessed a unique immune profile characterized by T-cell exhaustion, elevated CXCL13 expression in CD4+ T helper–like and CD8+CXCL13+ exhausted T cells, more mature tertiary lymphoid structures, and fewer desert immunophenotypes. Conversely, ICC displayed an inflamed immunophenotype with an enrichment of IFN-related pathways and high expression of LGALS1 in activated regulatory T cells, associated with immunosuppression. Inhibition of LGALS1 reduced tumor growth and regulatory T-cell prevalence in ICC mouse models. Overall, this study unveils T-cell diversity across BTC subtypes at the single-cell and spatial level that could open paths for tailored immunotherapies. Significance: Single-cell and spatial analyses detailed the T-cell characteristics specific to anatomic subtypes of biliary tract cancer, identifying unique immunologic features that could potentially be harnessed to improve patient outcomes.

3 August 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
KLKun Liu
Kun Liu
SHShengyuan He
Shengyuan He
SSShangqin Sun
Shangqin Sun
XZXinxin Zhang
Xinxin Zhang
YHYanzhen He
Yanzhen He
YXYun Xiao
Yun Xiao
The remarkable success of cancer immunotherapy has revolutionized cancer treatment, emphasizing the importance of tumor–immune interactions in cancer evolution and treatment. Cancer immunoediting describes the dual effect of tumor–immune interactions: inhibiting tumor growth by destroying tumor cells and facilitating tumor escape by shaping tumor immunogenicity. To better understand tumor–immune interactions, it is critical to develop computational methods to measure the extent of cancer immunoediting. In this review, we provide a comprehensive overview of the computational methods for quantifying cancer immunoediting. We focus on describing the basic ideas, computational processes, advantages, limitations, and influential factors. We also summarize recent advances in quantifying cancer immunoediting studies and highlight future research directions. As the methods for quantifying cancer immunoediting are continuously improved, future research will further help define the role of immunity in tumorigenesis and hopefully provide a basis for the design of new personalized cancer immunotherapy strategies.

16 January 2026 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
LDLantian Deng
Lantian Deng
WLWei Liu
Wei Liu
JXJinyuan Xu
Jinyuan Xu
BZBo Zhang
Bo Zhang
SHShengyuan He
Shengyuan He
YXYun Xiao
Yun Xiao
Single-cell studies have significantly advanced our understanding of the transcriptional and functional heterogeneity in cancers. Recent studies have identified distinct states of cancer, immune, and stromal cells in the tumor microenvironment (TME), with growing evidence highlighting their clinical significance and therapeutic potential. Here, we present CancerSEA-X, an expanded version of CancerSEA that offers a comprehensive atlas of TME cell states. CancerSEA-X integrates 25 cancer cell states, 105 immune cell states, and 26 stromal cell states from systematically curated publications. Combining 239 single-cell datasets across 32 cancer types, encompassing over 9 million cells from 2120 patients, CancerSEA-X provides functional activity spectra and cancer-specific gene associations for these 156 cell states. These cell state-gene relationships were mapped onto networks, providing a systematic view of the TME. To improve usability, we redesigned the user interface to feature cell state characterization, state-gene correlation analysis, and interactive visualization of cell state-gene networks, enabling researchers to comprehensively explore these states and their functional relevance. Overall, CancerSEA-X serves as a valuable platform for investigating TME cell states, deepening our understanding of cancer heterogeneity, and potentially advancing the design of more effective clinical therapies. CancerSEA-X is freely available at http://biocc.hrbmu.edu.cn/CancerState.

1 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MSMengxiong Sun
Mengxiong Sun
QFQuan Fei
Quan Fei
HYHuan Yi
Huan Yi
ZLZhongyu Lu
Zhongyu Lu
YYYangyang Yu
Yangyang Yu
FBFanfeng Bu
Fanfeng Bu
E23528 Background: Osteosarcoma(OST) differs from soft tissue sarcoma(STS) in terms of pathology and chemotherapy, but there is partial overlap in targeted therapy. Few articles have described the differences in genetic profiles of OST and STS in Chinese patients based on extensive sample data, at this point, identifying the difference genomic characterization between them may provide new drug targets for clinical diagnosis and treatment. Methods: A 551-gene targeted panel of DNA-based Next Generation Sequencing (NGS) assay was performed on tumor tissue(n = 613) and plasma(n = 136) obtained from STS(n = 586) and OST(n = 163) patients, the majority were male(n = 430, 57.4%), median age was 49(range 1-87), 101 patients also measured additional 67 gene fusions based on RNA-seq in tumor samples. All variants (SNV, INDEL, CNV and fusion) were entered into the result analysis. PD-L1expression was tested by IHC(SP263). Results: The top 5 mutant genes were TP53(28%), CDK4(20%), MDM2(18%), CDKN2A(15%), CDKN2B(15%) in STS, and TP53(26%), MYC(19%), CDK4(18%), MUC16(13%), CDKN2B(13%) in OST respectively. MDM2(18% vs 10%, p = 0.030) and PTEN(11% vs 4%, p = 0.007) were significantly higher in STS, while GNAS(7% vs 3%, p = 0.045) and IDH1(5% vs 1%, p = 0.002) were more common in OST. The most frequently affected pathways were Cell cycle(42%), Genome integrity(34%), RTK signaling(27%) in STS and Cell cycle(36%), Genome integrity(33%), transcription factor(28%) in OST. Additional significantly co-altered genes were RB1/PTEN, LRP1B/FAT3, FAT2/SPTA1 in STS, and MUC16/LRP1B, LRP1B/POLE, MED12/STAG2 in OST. More rare fusions were identified in STS. Wefound 15 PTPRB fusions, 14 of which were from STS. MDM2 fusions only detected in STS, 8 of which were from liposarcoma. Almost all patients were defined as MSS(625/629), with only 4 MSI-L and no MSI-H. 2.9%(17/589) STS and 3.1%(5/163) OST scored as TMB-H(≥10.00 Muts/Mb). TP53(p<0.001), MUC16(p<0.001), LRP1B(p<0.001), FAT3(p<0.001)were more likely to appear in the TMB-H group of STS, while MUC16(p<0.001) was more likely to appear in TMB-H group of OST. 32.3%(83/257) STS and 29.6%(8/27) OST were PD-L1-positive(PD-L1≥1%). In STS, PDCD1LG2(p<0.001), CD274(p<0.001) and JAK2 (p = 0.001)were more common in the PD-L1-positive group, while MDM4 (p = 0.018) and PARP1(p = 0.003)were more common in the PD-L1-negtive group. There were no statistically significant differences due to limited PD-L1 data in OST. Conclusions: The analysis revealed that there are some differences in genetic profiles between Chinese OST and STS, which may provid more precise basis for personalized targeted therapy and immunotherapy.

17 June 2026
Verified
Other
Open access
JNJianhua Nie
Jianhua Nie
SZShuyuan Zhang
Shuyuan Zhang
YGYing Guo
Ying Guo
CLCaiqi Liu
Caiqi Liu
JSJiaqi Shi
Jiaqi Shi
TZTongsen Zheng
Tongsen Zheng
Single cell sequencing statistics.

17 June 2026
Verified
Other
Open access
JNJianhua Nie
Jianhua Nie
SZShuyuan Zhang
Shuyuan Zhang
YGYing Guo
Ying Guo
CLCaiqi Liu
Caiqi Liu
JSJiaqi Shi
Jiaqi Shi
TZTongsen Zheng
Tongsen Zheng
The CXCL13+ T cells are associated with the maturation of TLS in ECC.